SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases. SinoMab is headquartered in Hong Kong with its R&D base in Hong Kong and production base in Chinese mainland.

The Company's flagship product SM03 (Suciraslimab) is a potential global first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. Suciraslimab has completed the Phase III clinical trial for RA in China. In addition, the Company possesses other potential first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren’s syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases with major unmet clinical needs.